Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment (PCV)

Trial Profile

Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment (PCV)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Age-related macular degeneration; Choroidal neovascularisation
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2017.
    • 30 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2016.
    • 30 Aug 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top